Filtricine Preclinical Results Published

Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology, Targeted Nutrients Deprivation (TND), have been published in Nutrition and Cancer.

“Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids”

Open source link: https://www.tandfonline.com/doi/full/10.1080/01635581.2021.2013904

Filtricine’s core medical food technology is the deprivation of non-essential amino acids (NEAAs) to manage cancer.  Cancer cells, but not normal cells, require those NEAAs due to their heightened and rewired metabolism.  Mice fed TND medical food diet with implanted human-derived tumors showed marked reduction in tumor growth. In combination with chemotherapy and immunotherapy, TND diet enhanced the efficacy of tumor suppression. TND diet was entirely safe in mice.

Filtricine is developing a human version of the TND diet, Tality™, as a medical food to manage cancer.  Filtricine is sponsoring a clinical study at Stanford University School of Medicine for the use of Tality™ in the management of prostate cancer. Tality™ is available to prostate cancer patients through this trial.

If you are interested in joining the trial, please contact the trial coordinator:

Deirdre Crommie at 650-387-7797 or dcrommie@stanford.edu

Tality™ is also available to all cancer patients for free through a volunteer study. Please contact volunteer@filtricine.com if you would like to know more.